Does the media favor KRYS or KOD?

In the previous week, Krystal Biotech had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Krystal Biotech and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Krystal Biotech's score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, KOD or NUVL?

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is KOD or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Nuvalent N/A -40.11% -35.43%

Does the media refer more to KOD or NUVL?

In the previous week, Nuvalent had 9 more articles in the media than Kodiak Sciences. MarketBeat recorded 11 mentions for Nuvalent and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Nuvalent's score of 0.15 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IBRX or KOD?

In the previous week, ImmunityBio had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat ImmunityBio's score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, QGEN or KOD?

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.59 $424.88M $1.91 19.08 Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is QGEN or KOD more profitable?

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Kodiak Sciences N/A -253.85% -81.48%

Does the media prefer QGEN or KOD?

In the previous week, Qiagen had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 18 mentions for Qiagen and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Qiagen's score of -0.43 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, KOD or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is KOD or IMVT more profitable?

Immunovant's return on equity of -65.66% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Immunovant N/A -65.66% -59.88%

Does the media refer more to KOD or IMVT?

In the previous week, Immunovant had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 8 mentions for Immunovant and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Immunovant's score of 0.35 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kodiak Sciences (KOD) Competitors

$33.87 +0.65 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$33.96 +0.09 (+0.27%)

As of 05:29 PM Eastern

Compare

KOD vs. KRYS, NUVL, IBRX, QGEN, and IMVT

Should you buy Kodiak Sciences stock or one of its competitors? MarketBeat compares Kodiak Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kodiak Sciences include Krystal Biotech (KRYS), Nuvalent (NUVL), ImmunityBio (IBRX), Qiagen (QGEN), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Kodiak Sciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Krystal Biotech has a net margin of 53.92% compared to Kodiak Sciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Kodiak Sciences	N/A	-253.85%	-81.48%

Krystal Biotech presently has a consensus price target of $324.11, indicating a potential upside of 7.39%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 24.43%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, Krystal Biotech had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Krystal Biotech and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Krystal Biotech's score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Kodiak Sciences on 10 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Nuvalent?

Kodiak Sciences (NASDAQ:KOD) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Nuvalent	N/A	-40.11%	-35.43%

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 24.43%. Nuvalent has a consensus price target of $141.24, suggesting a potential upside of 56.61%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts clearly believe Nuvalent is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvalent had 9 more articles in the media than Kodiak Sciences. MarketBeat recorded 11 mentions for Nuvalent and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Nuvalent's score of 0.15 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Summary

Nuvalent beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks.

How does Kodiak Sciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 97.77%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 24.43%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Kodiak Sciences has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.38	-$351.40M	-$0.85	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Kodiak Sciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Kodiak Sciences	N/A	-253.85%	-81.48%

In the previous week, ImmunityBio had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat ImmunityBio's score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImmunityBio beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks.

How does Kodiak Sciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Qiagen had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 18 mentions for Qiagen and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Qiagen's score of -0.43 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.59	$424.88M	$1.91	19.08
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Qiagen currently has a consensus target price of $44.98, suggesting a potential upside of 23.41%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 24.43%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

Qiagen beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Immunovant?

Kodiak Sciences (NASDAQ:KOD) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Immunovant's return on equity of -65.66% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Immunovant	N/A	-65.66%	-59.88%

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 24.43%. Immunovant has a consensus price target of $37.33, suggesting a potential upside of 19.85%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Kodiak Sciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Immunovant had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 8 mentions for Immunovant and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.93 beat Immunovant's score of 0.35 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kodiak Sciences has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunovant is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Summary

Kodiak Sciences beats Immunovant on 8 of the 12 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.12B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-8.12	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	11.40	6.63	9.84	6.72
Net Income	-$229.97M	$24.20M	$3.57B	$337.19M
7 Day Performance	-3.48%	-3.24%	-1.16%	0.48%
1 Month Performance	-22.95%	0.53%	3.85%	5.07%
1 Year Performance	759.64%	47.24%	27.40%	34.25%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	2.6223 of 5 stars	$33.87 +2.0%	$42.14 +24.4%	+822.8%	$2.12B	N/A	N/A	90
KRYS Krystal Biotech	3.2722 of 5 stars	$299.45 flat	$324.11 +8.2%	+133.9%	$8.83B	$389.13M	40.03	210	Analyst Forecast
NUVL Nuvalent	3.439 of 5 stars	$102.12 flat	$140.29 +37.4%	+18.4%	$8.07B	N/A	N/A	40	News Coverage Analyst Forecast Insider Trade
IBRX ImmunityBio	2.4312 of 5 stars	$7.22 flat	$14.20 +96.7%	+170.8%	$7.56B	$113.29M	N/A	590	Analyst Forecast
QGEN Qiagen	4.1509 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-24.4%	$7.25B	$2.09B	18.40	5,654

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. KRYS, NUVL, IBRX, QGEN, and IMVT

How does Kodiak Sciences compare to Krystal Biotech?

Summary

How does Kodiak Sciences compare to Nuvalent?

Summary

How does Kodiak Sciences compare to ImmunityBio?

Summary

How does Kodiak Sciences compare to Qiagen?

Summary

How does Kodiak Sciences compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. KRYS, NUVL, IBRX, QGEN, and IMVT

How does Kodiak Sciences compare to Krystal Biotech?

Do insiders and institutionals believe in KRYS or KOD?

Is KRYS or KOD more profitable?

Do analysts prefer KRYS or KOD?

Which has more volatility & risk, KRYS or KOD?

Which has stronger valuation and earnings, KRYS or KOD?

Does the media favor KRYS or KOD?

Summary

How does Kodiak Sciences compare to Nuvalent?

Which has higher valuation & earnings, KOD or NUVL?

Is KOD or NUVL more profitable?

Do analysts recommend KOD or NUVL?

Do insiders & institutionals hold more shares of KOD or NUVL?

Does the media refer more to KOD or NUVL?

Which has more volatility & risk, KOD or NUVL?

Summary

How does Kodiak Sciences compare to ImmunityBio?

Do insiders and institutionals believe in IBRX or KOD?

Do analysts recommend IBRX or KOD?

Which has more risk & volatility, IBRX or KOD?

Which has higher earnings & valuation, IBRX or KOD?

Is IBRX or KOD more profitable?

Does the media favor IBRX or KOD?

Summary

How does Kodiak Sciences compare to Qiagen?

Do insiders & institutionals believe in QGEN or KOD?

Does the media prefer QGEN or KOD?

Which has higher valuation and earnings, QGEN or KOD?

Do analysts rate QGEN or KOD?

Which has more volatility and risk, QGEN or KOD?

Is QGEN or KOD more profitable?

Summary

How does Kodiak Sciences compare to Immunovant?

Is KOD or IMVT more profitable?

Do analysts rate KOD or IMVT?

Does the media refer more to KOD or IMVT?

Which has more volatility & risk, KOD or IMVT?

Do insiders and institutionals hold more shares of KOD or IMVT?

Which has higher earnings & valuation, KOD or IMVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools